Landmark Therapeutics is a late-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders, primarily schizophrenia, bipolar depression, and major depressive disorder. The company's lead product is LB-102, an optimized derivative of amisulpride (a proven second-generation antipsychotic with decades of clinical use globally) designed to achieve therapeutic efficacy at lower once-daily doses with improved tolerability and the potential for long-acting injectable formulation. Landmark earns revenue potential through the future approval and commercialization of LB-102 and related product candidates, retaining global development and commercialization rights while operating through partnerships with contract manufacturers and select commercial partners.